Recombinant Adeno-associated Viruses (rAAV) Retargeted For Cancer Therapy | 49579
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

6th International Conference on Vaccines and Immunology

Geneva, Switzerland

3rd European Congress on Virology

Geneva, Switzerland
Google scholar citation report
Citations : 1600

Journal of Biotechnology & Biomaterials received 1600 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Recombinant adeno-associated viruses (rAAV) retargeted for cancer therapy

11th World Congress on Biotechnology and Biotech Industries Meet

Kristian M Muller

Bielefeld University, Germany

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.052

Virus-based suicide gene therapy with enzymes also called virus-directed enzyme mediated prodrug therapy (VDEPT) delivers genes for prodrug-activating enzymes to tumor cells. This approach leverages modular design of various cellular and transcriptional targeting and detargeting approaches with established enzyme-prodrug combinations. We are testing EGF-receptor dependent gene delivery by fusing binding domains (DARPin, Affibody) to capsid proteins or by inserting computationally designed peptides into capsid loop structures. For prodrug activation, we utilize thymidine kinase or cytosine deaminase in combination with ganciclovir or 5-fluorouracil, respectively. At cellular level, we achieve tumor-marker specific binding, transduction and ultimately specific killing. The approach is facilitated by a modular vector design and the use of fluorescent proteins as genes of interest. Effects on target cells were analyzed by viability assays as well as microscopy and flow cytometry.

Kristian Müller is a professor of cellular and molecular biotechnology at Bielefeld University, Germany. He was an Assistant Professor and Group Leader at the University of Freiburg and the University of Potsdam. Prior to his independent career he has worked as a Postdoctoral Scientist at the University of California at Berkeley and received his PhD from the University of Zurich and Diploma in Biochemistry from the University of Hannover. Within the realm of protein engineering and synthetic biology he performs basic research and develops technology, which he utilizes to drive innovations such as cancer therapeutics.

Email: [email protected]